<DOC>
	<DOC>NCT00332826</DOC>
	<brief_summary>The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.</brief_summary>
	<brief_title>Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>A clinical diagnosis of Step 1 to 3 asthma as per the NAEPP guidelines Clinical diagnosis of Type 1 or Type 2 diabetes mellitus for at least 1 year Current stable antidiabetic regimen (insulin alone or in combination with oral antihyperglycemic agents) Subjects must exhibit &lt;30% variability in PEF measurements during the 2 week run in period. Subjects must not meet any criteria for exacerbations of asthma during the 2 week run in period Body mass index (BMI) &lt; 40kg/m2 HbA1c &gt;6.0% to &lt;11.5% Severe complications of diabetes in the opinion of the investigator Seizure disorder Significant cardiovascular dysfunction and/or history within 3 months of screening Hypertension with systolic blood pressure of !80 mm Hg and/or diastolic blood pressure &gt;110 mm HG at screening despite pharmacologic therapy. Clinical nephrotic syndrome or renal dysfunction or disease Total daily insulin requirement of &gt;1.4 U/kg body weight Clinical diagnosis of Step 4 asthma Use of &gt;6 puffs/day of fast acting bronchodilator Currently using an insulin delivery pump Use of Pramlintide acetate or any incretins must be discontinued 8 weeks prior to screening Two or more severe hypoglycemic episodes within the past 6 months. Any hospitalization or emergency room visit due to poor diabetic control with 6 months of screening. Current use of systemic steroids Subjects who currently smoke tobacco or who have smoked within the past 6 months Urine cotinine test of &gt; 100ng/ml Current drug or alcohol abuse Clinically significant abnormalities on screening laboratory evaluation Cancer within the past 5 years or any history of lung neoplasms History of active and/or cirrhotic hepatic disease and/or abnormal liver enzymes. Active infection or history of severe infection with 30 days of screening. Anemia History of anaphylaxis and/or angioneurotic edema Diagnosis of chronic obstructive pulmonary disease (COPE) Previous exposure to any inhaled insulin product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Inhaled insulin</keyword>
	<keyword>Diabetes Type I and II with Asthma</keyword>
</DOC>